| | Treatment arms | Costs () | Vision-years | QALYs | ICER versus usual care | Comments |
| | Predominantly classic | | | | | | | Usual care | 8,618.5 | 2.38 | 3.97 | | | | PDT | 18,292.5 | 3.23 | 4.19 | 44,333 | Dominated | | Ranibizumab | 29,468.3 | 4.16 | 4.55 | 36,089 | Not cost-effective | | Bevacizumab | 9,232.8 | 3.92 | 4.46 | 1,258 | Cost-effective | | Minimally classic | | | | | | | Usual care | 8,663.5 | 2.80 | 4.10 | | | | PDT | 18,289.1 | 3.11 | 4.19 | 112,992 | Dominated | | Ranibizumab | 29,480.0 | 3.77 | 4.31 | 102,828 | Not cost-effective | | Bevacizumab | 9,242.8 | 3.59 | 4.26 | 3,803 | Cost-effective | | Occult with no classic | | | | | | | Usual care | 8,594.9 | 2.08 | 3.90 | | | | PDT | 18,240.1 | 2.43 | 4.01 | 91,424 | Dominated | | Ranibizumab | 29,465.1 | 3.61 | 4.26 | 58,790 | Not cost-effective | | Bevacizumab | 9,227.8 | 3.44 | 4.21 | 2,066 | Cost-effective |
|
|
